In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vysis Preps For Prime Time

Executive Summary

Tiny Vysis scored big this spring, winning the backing of two major therapeutic and diagnostic companies for its products. But is its core technology ready for prime time? Vysis sees an opportunity to expand use of its FISH diagnostics technology beyond niche applications in the clinical market. But skeptics say the technology is too complex and expensive for routine clinical use.
Advertisement

Related Content

Clinical Update (03/2007)
An Intelligent Evolution for Dako and Cytomation
An Intelligent Evolution for Dako and Cytomation
Stepping Into the Race to Detect Fetal Cells in Maternal Blood
Targeted Therapeutics: Linking EGF Receptor Drugs to Diagnostics
BD's Progress in Molecular Markers
Clinical Laboratories' Amazing Comeback
A FISH on the Line
Rates of Return in Diagnostics IPOs by Market Cap
Emerging Opportunities in In Situ Hybridization

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV001693

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel